In November, we added 93 citations in DIDB, including 45 in vitro (with 26 articles published in November 2024) and 48 in vivo articles (with 34 articles published in November 2024).
5 NDA/BLAs approved in 2024, including arimoclomol (MIPLYFFA), inavolisib (ITOVEBI), seladelpar (LIVDELZI), zolbetuixmab(VYLOY), and xanomeline and trospium (COBENFY) were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.